| Assessment Status | Full HTA Assessment |
| HTA ID | - |
| Drug | Pregabalin |
| Brand | Lyrica® |
| Indication | For the treatment of Generalised Anxiety Disorder. |
| Assessment Process | |
| Full submission received from Applicant | 12/09/2014 |
| NCPE assessment completed | 15/12/2014 |
| NCPE assessment outcome | Reimbursement Not Recommended at the Submitted Price. |
The NCPE Review Group concludes that, at the current price, pregabalin (Lyrica®) is not cost effective as a first line treatment for generalised anxiety disorder. Pregabalin may be considered cost effective (as a third line treatment) in patients who have relapsed or who have not responded to cognitive behavioural therapy (first line treatment) and who subsequently have relapsed or have not responded to escitalopram or venlaflaxine (first linedrug treatment).
